FDA clears Senseonics' 365-day Eversense CGM implant Meanwhile, Senseonics, along with its partner Ascensia Diabetes Care, received an agency green light last September for its year-long ...

Dublin, April 29, 2025 (GLOBE NEWSWIRE) -- The "Spain Continuous Glucose Monitoring Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. Spain's ...

Eversense 365 is developed by Senseonics and brought to patients by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE: 6523). As the only implantable CGM available, it offers ...

Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also ...

Did you use a glucose meter to check your blood glucose level many times, but it gives you different results? Did you use different glucose meters to check your glucose level? And they also result in ...

Cell Press and The Lancet have introduced an automated method of transferring a manuscript from any Cell Press or The Lancet title to eBioMedicine. This automated transfer allows authors to move their ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.